Biotech Breakthrough: Serina Therapeutics Secures Insider Led Financing for SER-252 Registrational Trial in Neurology Pipeline – ($SER $BHVN $XBI )

By John F. Heerdink, Jr.

Serina Therapeutics (NYSE American: SER), a biotechnology firm headquartered at the HudsonAlpha Institute in Huntsville, Alabama, has rapidly advanced its position in the neurology pipeline by leveraging its proprietary POZ Platform™. Over the past several months, the company has unveiled a series of notable updates that underscore its clinical and financial momentum.

$20 Million Financing Fuels Parkinson’s Trial

On September 9, Serina announced a flexible financing agreement granting access to up to $20 million, led by Board Director Greg Bailey, MD. Structured as an unsecured convertible note distributed in five tranches, the funding is specifically designed to support the Phase 1b registrational study of SER-252, the company’s lead candidate targeting advanced Parkinson’s disease. Each tranche carries 100% warrant coverage, providing a potential additional $20 million if fully exercised. The financial structure enables Serina to deploy capital aligned with clinical trial milestones—an approach endorsed by the board and management as both prudent and essential given the complexities of late-stage drug development. Serina also continues to evaluate non-dilutive and strategic alternatives for expanding its funding base.

Greg_CircleHeadshot_Photo - Juvenescence

Greg Bailey (pictured above) is the Executive Chairman of Juvenescence, clinical-stage drug development company dedicated to extending healthy lifespan through innovative medicines, which he co-founded in 2017. He also led the seed financing of Biohaven Pharmaceuticals Holding Company Ltd. and joined the board in 2014. He is also a board director of public companies Biohaven Pharmaceuticals (NYSE – BHVN) and Portage Biotech (NASDAQ – PRTG). Dr. Bailey also founded and served as a director of a number of private and public companies and previously served as a managing partner of Palantir Group, Inc., a merchant bank involved in a number of biotech company startups and financings. He was also an independent director of Medivation, Inc. (MDVN:NASDAQ), acquired by Pfizer in 2016. Dr. Bailey practiced emergency medicine for ten years before entering finance. Dr. Bailey received his M.D. from the University of Western Ontario.

Progress on SER-252 and Regulatory Milestones

The core of Serina’s clinical push is SER-252, a next-generation formulation of apomorphine leveraging the POZ platform for continuous dopaminergic stimulation via subcutaneous injection. This technology aims to address the unmet needs of approximately 180,000 advanced Parkinson’s patients in the U.S. and Europe who struggle with motor fluctuations and limited on-time control under current therapies. Following recent FDA feedback, Serina plans to submit its IND application in Q4 2025, with patient dosing in Australia expected to begin in parallel. U.S. enrollment is projected for Q1 2026. The Phase 1b study will use a randomized, double-blind, placebo-controlled design to evaluate safety, pharmacokinetics, and exploratory efficacy, including established motor function endpoints. Strategic delivery partnerships, such as with Enable Injections’ enFuse™ wearable platform, are expected to further improve patient experience.

Corporate Positioning and Expansion

Serina’s recent news cycle has also covered corporate governance and development. Grants of inducement stock options to new employees reflect long-term alignment with shareholders, while the upcoming annual stockholders meeting in November signals continued transparency and engagement. The company’s investor communications emphasize its ability to progress even amid broader biotech sector volatility. Other pipeline candidates—including SER-270 for tardive dyskinesia (TD)—remain on track, with IND-enabling studies anticipated to commence shortly. TD is a disabling and often stigmatizing movement disorder caused by long-term exposure to antipsychotic medications. It predominantly affects those with chronic psychiatric conditions such as schizophrenia and bipolar disorder who may have difficulty adhering to complex daily medication regimens. While oral VMAT2 inhibitors are the only approved class for TD, uptake remains modest due to underdiagnosis, low disease awareness among clinicians, and the challenges of ensuring daily medication adherence in complex, high-risk populations. It is estimated that fewer than 30% of U.S. TD patients are diagnosed, and less than half of those receive pharmacologic treatment. Despite these challenges, the U.S. TD market exceeded $3.7 billion in sales in 2024, driven by increased recognition and broader reimbursement. Analysts project the market to grow to $5.4 billion by 2030, underscoring the significant opportunity for differentiated therapies that address adherence, access, and administration barriers.

Spotlight on the POZ Platform

The foundation for Serina’s approach is the POZ Platform™, which is based on a synthetic, water soluble, low viscosity polymer called poly (2-oxazoline). During the synthesis steps, a predictable amount of drug is incorporated on the backbone of the polymer using pendant alkyne groups and metal catalyzed “click chemistry”. The POZ Platform ™ technology provides greater control in drug loading, and the rate of release of attached drugs can often be more precisely controlled. Drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood. Further, the technology is optimized for small molecules and can also be applied to other classes of molecules including proteins and peptides. The application of the platform has been further expanded to optimize the performance of antibody drug conjugates and lipid nanoparticles. This versatility remains a central theme in Serina’s corporate narrative and continues to attract both investor and strategic partner attention.

Featured Presentation From Serina August 2025

Learn more by reviewing Serina’s current powerpoint, titled Next Generation Drug Product Optimization Platform. Enabling Improvements of Multiple Drug Modalities.

The Sum…

Serina Therapeutics’ (NYSE American: SER) recent momentum is emblematic of a biotech sector increasingly focused on targeted innovation and careful capital allocation—and will be closely watched by both Wall Street and the neurological disease community in the lead-up to its key regulatory inflection points.